Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.

Item

http://www.wikidata.org/entity/Q25257587

Q25257587

about

Emotional and sexual concerns in women undergoing pelvic surgery and associated treatment for gynecologic cancer Chemotherapy-induced peripheral neurotoxicity: a critical analysis Vascularization of the dorsal root ganglia and peripheral nerve of the mouse: implications for chemical-induced peripheral sensory neuropathies A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials Factors associated with grade 3 or 4 treatment-related toxicity in women with advanced or recurrent cervical cancer: an exploratory analysis of NRG Oncology/Gynecologic Oncology Group trials 179 and 204.[EXPRESS] Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy; cause and effect?Persistent mobility disability after neurotoxic chemotherapy Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial Nociceptor beta II, delta, and epsilon isoforms of PKC differentially mediate paclitaxel-induced spontaneous and evoked pain.Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer.[Chemotherapy-induced peripheral neuropathies: an integrative review of the literature].Effect of acetyl-l-carnitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin.Contemporary quality of life issues affecting gynecologic cancer survivors.An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat Limitations to the use of carboplatin-based therapy in advanced ovarian cancer Chemotherapy-induced peripheral neuropathy: Current status and progress.Survivors of gynecologic malignancies: impact of treatment on health and well-being Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine Quality of life considerations in gynecologic cancer. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.Health-related quality of life in ovarian cancer patients and its impact on clinical management Supportive care for women with gynecologic cancers.Treatment of recurrent epithelial ovarian cancer Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment.A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review.Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge.The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer.Depletion of nerve growth factor in chemotherapy-induced peripheral neuropathy associated with hematologic malignancies Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy.Bilateral Blindness Following Chemoradiation for Locally Advanced Oropharyngeal Carcinoma.Taxane-Induced Peripheral Neurotoxicity.Discussion: session 2.Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO A When nonplatinum is the answer: the role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer.Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial.Neuro- and nephroprotective effect of grape seed proanthocyanidin extract against carboplatin and thalidomide through modulation of inflammation, tumor suppressor protein p53, neurotransmitters, oxidative stress and histology.

P2860

Q26773707-DAB9DDA3-EDE5-4AA2-A0AC-2AE0D0BDD8F6 Q27010318-ADB8B09B-543A-4287-9BC8-8CEC242F7C8B Q33324545-18E7C60E-5D8D-45E7-AB23-97631B05B6C0 Q33387755-F1F3A2C8-4D27-47B2-A5C5-CBF813072972 Q33409319-4AD413BA-BD22-4A53-82FF-160B2A5FF1F2 Q33418750-067E3222-8C1F-48B3-A70E-653BAFF294AB Q33824948-E56B8C57-7ADB-4243-9BD0-0C6510E69F07 Q34259315-E8C2B320-620F-4651-BE43-F77A6D2CFDC2 Q34413664-84A2F174-798C-40B9-AFD7-CC26D02D129B Q35187458-F4282731-2145-4DC1-A5B6-75E605417C8E Q35210260-5095D1EA-A314-44AD-BA80-23C6FECF4D07 Q35636254-8B1325DA-2B68-414E-B29E-932F59D12FFF Q35967152-9692E989-DBDA-466A-9EE5-028D4ECE3270 Q36067725-1034E98B-C4CE-4121-AD38-1B73A50E4D6B Q36094403-59EB6DAC-69FF-4C44-919E-1DBB3DF416C1 Q36382337-89E24A1B-0863-40DC-A445-C9D3BADCF02E Q36421901-19B74617-5925-442D-A0E8-FDD75464A87F Q36553964-1CF7CD2B-2EC3-4B6E-8494-DE56B3028117 Q36636831-0922D6D4-3D19-4985-AC4A-0296FD2DD80C Q36679733-E5F08F13-382C-46AB-B609-5D0D37CD1E60 Q37036780-FA4D340E-A4A4-4CCD-9CA7-9CC1C8159E3F Q37086010-F138FAAD-87BF-4D3E-A977-5CD8DFBCB3AA Q37224624-0A1C74A9-0E89-4308-8FF1-A43E064B552D Q37273523-0767BB32-20FB-4D78-BB15-719F401E7CAE Q37397508-17508B3D-0EF5-4C7A-9DC8-A84A7032D5FA Q37662576-CA388A1D-8A74-4167-B4D1-F918AE38BB8A Q38995032-461E2B12-94EC-4581-AF9F-6CFEDC36F34C Q39282981-820001F9-002B-4B14-9E1C-0D20438036F3 Q41475920-6ED8C8FC-BEE3-4CE0-81C8-C37E0B991358 Q42750577-7A20AA5E-3BF9-4956-B4FB-5428EEAB2F5C Q43164316-43322692-FE89-4768-A658-017E0A969A96 Q45759415-4C4F7449-E3DD-4D6D-9F6F-7CC6DF99B040 Q46190587-54679D75-4A9C-4056-83CB-1C3891924E8F Q47631494-3FC05B2F-172C-4579-9AAC-1F6EC2675DE2 Q47903322-214099D2-60B1-4A4F-B678-1B78EDC004B5 Q47979421-55BF3B03-C99F-420F-B07F-D25B4EDA05F6 Q55018342-D87C5BBE-8EEB-4F88-A391-DE4291461A63

P2860

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.

Item

http://www.wikidata.org/entity/Q25257587

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Residual neurotoxicity in ovar ...... r (MITO-4) retrospective study

@nl

Residual neurotoxicity in ovar ...... (MITO-4) retrospective study.

@ast

Residual neurotoxicity in ovar ...... (MITO-4) retrospective study.

@en

type

Item

label

Residual neurotoxicity in ovar ...... r (MITO-4) retrospective study

@nl

Residual neurotoxicity in ovar ...... (MITO-4) retrospective study.

@ast

Residual neurotoxicity in ovar ...... (MITO-4) retrospective study.

@en

prefLabel

Residual neurotoxicity in ovar ...... r (MITO-4) retrospective study

@nl

Residual neurotoxicity in ovar ...... (MITO-4) retrospective study.

@ast

Residual neurotoxicity in ovar ...... (MITO-4) retrospective study.

@en

P1476

Residual neurotoxicity in ovar ...... (MITO-4) retrospective study.

@en

P2093

Alessandra Vernaglia Lombardi

http://www.w3.org/2001/XMLSchema#string

Andrea de Matteis

http://www.w3.org/2001/XMLSchema#string

Antonio Febbraro

http://www.w3.org/2001/XMLSchema#string

Bruno Massidda

http://www.w3.org/2001/XMLSchema#string

Carmela Pisano

http://www.w3.org/2001/XMLSchema#string

Francesco Perrone

http://www.w3.org/2001/XMLSchema#string

Giacomo Cartenì

http://www.w3.org/2001/XMLSchema#string

Giampietro Gasparini

http://www.w3.org/2001/XMLSchema#string

Giovanni Di Vagno

http://www.w3.org/2001/XMLSchema#string

Giovanni Scambia

http://www.w3.org/2001/XMLSchema#string

P2860

Nonparametric Estimation from Incomplete Observations

Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine.

Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies.

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

Neurotoxicity of taxanes: symptoms and quality of life assessment.

Amifostine protects against chemotherapy-induced neurotoxicity: an in vitro investigation.

P2888

1471-2407-6-5

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4258160

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/1471-2407-6-5

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Giovanni Scambia

P577

2006-01-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7372719

http://www.w3.org/2001/XMLSchema#string

P6179

1053639084

http://www.w3.org/2001/XMLSchema#string

P698

16398939

http://www.w3.org/2001/XMLSchema#string

P921

P932

1361775

http://www.w3.org/2001/XMLSchema#string

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.

about

P2860

P2860

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P3181

P356

P407

P433

P478

P50

P577

P5875

P6179

P698

P921

P932

P3181

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P3181

P356

P407

P433

P478

P50

P577

P5875

P6179

P698

P921

P932